. Author manuscript; available in PMC: 2013 Feb 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2011 Dec 5;21(2):368–375. doi: 10.1158/1055-9965.EPI-11-0916

Table 3.

Association between genetic variation in CASR and GC and measures of metachronous colorectal neoplasia

Colorectal Neoplasia Outcomes (N = 1439)

	Distal³ N = 343 (24.0%)			Proximal³ N = 473 (33.1 %)			Recurrence N = 660 (45.9 %)			Villous N = 107 (7.5%)

	OR	95% CI		OR	95% CI		OR	95% CI		OR	95% CI
GC
PC1¹	0.98	0.90-1.06		1.00	0.93-1.07		0.99	0.92-1.05		0.90	0.80-1.03
PC2	1.03	0.94-1.13		0.97	0.89-1.05		0.99	0.92-1.07		1.01	0.88-1.16
PC3	0.97	0.85-1.09		0.96	0.86-1.07		0.95	0.86-1.06		0.88	0.72-1.09
PC4	0.95	0.79-1.14		0.95	0.81-1.12		0.96	0.82-1.12		1.00	0.75-1.35
LRT p- value²			0.87			0.83			0.86			0.41
*CASR*
PC1¹	1.03	0.97-1.12		1.05	0.99-1.13		1.03	0.97-1.10		1.01	0.90-1.14
PC2	0.98	0.91-1.07		1.00	0.93-1.07		1.01	0.94-1.08		0.99	0.87-1.12
PC3	1.00	0.92-1.10		0.92	0.85-1.00		0.95	0.88-1.03		0.96	0.83-1.12
PC4	0.95	0.86-1.06		1.03	0.93-1.13		1.02	0.93-1.12		1.10	0.92-1.31
PC5	1.10	0.97-1.25		1.01	0.90-1.14		1.07	0.96-1.20		1.03	0.83-1.27
LRT p- value²			0.57			0.17			0.39			0.85

An 80% explained-variance threshold is used for including principal components (PC) in the model.

P-value for each model is from a likelihood ratio test (LRT) with degrees of freedom equal to the number of principal components and is a test of gene-level associations.

The colorectal neoplasia outcome categories are not mutually exclusive.